Abstract
Inflammatory bowel diseases (IBD) are a collection of diseases associated with chronic inflammation in the intestinal mucosa and/or transmural involvement. IBD is divided into two main categories Crohn’s disease (CD) and ulcerative colitis (UC). While there is no cure for IBD, current therapies can only reduce the inflammatory process that causes the signs and symptoms of IBD and hopefully induce long-term remission. Improved treatment modalities for the complex IBD are still evolving. The increased understanding of the underlying immunopathology has helped identify new targeted treatment options in particular the use of stem cell treatments that are capable of modulating the immune system. Haematopoietic stem cells (HSC) and mesenchymal stromal cells (MSC) therapy are both being investigated as a treatment for IBD. MSC therapy is well tolerated and associated with minimal established side-effects compared to HSC therapy, which involves ablative chemotherapy. Currently, such stem cell therapy is not a standard of care regimen for IBD. However, it may potentially become the next generation treatment of choice, especially for severe refractory IBD patients.
Keywords: Crohn’s disease, haematopoietic stem cells, inflammatory bowel disease, mesenchymal stromal cells, stem cell therapy, ulcerative colitis.
Current Stem Cell Research & Therapy
Title:Management of Inflammatory Bowel Disease Using Stem Cell Therapy
Volume: 11 Issue: 1
Author(s): Mohammad R. Irhimeh and Julian Cooney
Affiliation:
Keywords: Crohn’s disease, haematopoietic stem cells, inflammatory bowel disease, mesenchymal stromal cells, stem cell therapy, ulcerative colitis.
Abstract: Inflammatory bowel diseases (IBD) are a collection of diseases associated with chronic inflammation in the intestinal mucosa and/or transmural involvement. IBD is divided into two main categories Crohn’s disease (CD) and ulcerative colitis (UC). While there is no cure for IBD, current therapies can only reduce the inflammatory process that causes the signs and symptoms of IBD and hopefully induce long-term remission. Improved treatment modalities for the complex IBD are still evolving. The increased understanding of the underlying immunopathology has helped identify new targeted treatment options in particular the use of stem cell treatments that are capable of modulating the immune system. Haematopoietic stem cells (HSC) and mesenchymal stromal cells (MSC) therapy are both being investigated as a treatment for IBD. MSC therapy is well tolerated and associated with minimal established side-effects compared to HSC therapy, which involves ablative chemotherapy. Currently, such stem cell therapy is not a standard of care regimen for IBD. However, it may potentially become the next generation treatment of choice, especially for severe refractory IBD patients.
Export Options
About this article
Cite this article as:
Irhimeh R. Mohammad and Cooney Julian, Management of Inflammatory Bowel Disease Using Stem Cell Therapy, Current Stem Cell Research & Therapy 2016; 11 (1) . https://dx.doi.org/10.2174/1574888X10666150728121738
DOI https://dx.doi.org/10.2174/1574888X10666150728121738 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Current Pharmaceutical Design Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Current Pharmaceutical Design The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Letters in Drug Design & Discovery Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Hyperthermia Associated Osteonecrosis in Young Patients with Pelvic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Transplantation and Other Uses of Human Umbilical Cord Blood and Stem Cells
Current Pharmaceutical Design Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Busulfan Use in Hematopoietic Stem Cell Transplantation: Pharmacology, Dose Adjustment, Safety and Efficacy in Adults and Children
Current Drug Safety Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry Adverse Events of Proton Pump Inhibitors: Potential Mechanisms
Current Drug Metabolism Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Recurrent Scalp Lesions from Glioblastoma: Case Report and Literature Review
Current Cancer Therapy Reviews Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets Mechanisms of Resistance to Imatinib in CML Patients: A Paradigm for the Advantages and Pitfalls of Molecularly Targeted Therapy
Current Cancer Drug Targets Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets